BioStock: Promore Pharma initiates patient recruitment

Last Wednesday, Solna-based Promore Pharma released its year-end report, and, on the same day, the company was able to communicate news regarding its phase II study with the candidate ensereptide. In accordance with the company’s timetable, the first patient has now been recruited for the study on scarring. BioStock contacted CEO Jonas Ekblom to find out more.

Read the full interview with Jonas Ekblom at biostock.se:

https://www.biostock.se/en/2022/02/promore-pharma-initiates-patient-recruitment/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se